Publications

The Lancet. Oncology

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

01-07-2026

The Lancet. Oncology

Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.

01-07-2026

NPJ breast cancer

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.

25-06-2026

European journal of cancer (Oxford, England : 1990)

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study.

13-06-2026

Breast (Edinburgh, Scotland)

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

01-06-2026

Nature communications

High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities.

19-05-2026

NPJ breast cancer

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

06-05-2026

NPJ breast cancer

Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort.

20-04-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

17-04-2026

Science translational medicine

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

18-03-2026

Nature cancer

Setting higher standards for reports of microbial species in human cancers.

01-03-2026

The Lancet. Oncology

MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.

01-03-2026

International journal of cancer

Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic status.

15-02-2026

British journal of cancer

Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond.

01-11-2025

Radiology

Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ.

01-11-2025

Insights into imaging

Image-guided biopsy of breast lesions-when to use what biopsy technique.

25-09-2025

European radiology

Watchful waiting for ductal carcinoma in situ: are we ready to step back?

01-08-2025

Cellular oncology (Dordrecht, Netherlands)

Absence of lipopolysaccharide (LPS) expression in breast cancer cells.

01-08-2025

British journal of cancer

Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.

01-06-2025

Cancer epidemiology

Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry.

01-06-2025

EBioMedicine

Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.

01-06-2025

NPJ breast cancer

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

29-05-2025

European radiology

Correction: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

01-04-2025

European journal of cancer (Oxford, England : 1990)

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.

25-02-2025

NPJ breast cancer

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.

13-02-2025

Clinical oncology (Royal College of Radiologists (Great Britain))

Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands-A Nationwide Overview From 2008 Until 2022.

01-02-2025

NPJ precision oncology

A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.

28-01-2025

Cancer discovery

Conquering Overtreatment of DCIS: Lessons from PRECISION.

13-01-2025

Nature

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

01-01-2025

Key Publication

European journal of cancer (Oxford, England : 1990)

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

01-12-2024

European radiology

Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

01-12-2024

Future oncology (London, England)

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ.

01-12-2024

Breast (Edinburgh, Scotland)

DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.

01-10-2024

British journal of cancer

Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.

01-09-2024

Breast cancer research : BCR

Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.

27-08-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

The Journal of pathology

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

01-07-2024

Lancet (London, England)

Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.

22-06-2024

The Lancet. Oncology

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.

01-05-2024

Cancer imaging : the official publication of the International Cancer Imaging Society

Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.

05-04-2024

ESMO open

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

01-03-2024

Breast cancer research and treatment

The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.

01-02-2024

The Journal of pathology

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.

01-02-2024

BMJ (Clinical research ed.)

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.

24-01-2024

Molecular oncology

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.

01-01-2024

Research square

Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.

13-12-2023

Insights into imaging

Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis.

05-12-2023

Cancer epidemiology

Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study.

01-12-2023

Breast cancer research : BCR

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

13-11-2023

BMJ (Clinical research ed.)

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

30-10-2023

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study.

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities.

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort.

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Setting higher standards for reports of microbial species in human cancers.

MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.

Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic status.

Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond.

Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ.

Image-guided biopsy of breast lesions-when to use what biopsy technique.

Watchful waiting for ductal carcinoma in situ: are we ready to step back?

Absence of lipopolysaccharide (LPS) expression in breast cancer cells.

Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.

Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry.

Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

Correction: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.

Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands-A Nationwide Overview From 2008 Until 2022.

A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.

Conquering Overtreatment of DCIS: Lessons from PRECISION.

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ.

DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.

Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.

Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.

Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.

Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.

Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis.

Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study.

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

This site uses cookies